Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05345717 · ClinicalTrials.gov registry record · Phase 1
Novel Desensitization Kidney Transplantation
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05345717 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 5 participants.
The verdict
NCT05345717, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This proposal's objective is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.
Interventions
- DRUG Belatacept Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2025-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05345717
The ClinicalTrials.gov registry entry for NCT05345717 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belatacept Injection is the first listed.
NCT05345717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05345717 about?
NCT05345717 is a clinical study titled "Novel Desensitization Kidney Transplantation". This proposal's objective is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.
What is the current status of trial NCT05345717?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-05-01. Estimated completion is 2025-09-12.
What interventions are being tested in trial NCT05345717?
The interventions under investigation include: Belatacept Injection (DRUG).
Who is sponsoring clinical trial NCT05345717?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.